The company's acquisition of BIOVECTRA is set to have enhanced its Contract Development and Manufacturing Organization ... report fourth-quarter 2024 results on Feb. 26. Evolus EOLS has an ...
The consensus mark for earnings is pegged at $1.27 per share ... to have enhanced its Contract Development and Manufacturing Organization business, particularly in oligonucleotides and CRISPR ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback